<DOC>
	<DOC>NCT00289367</DOC>
	<brief_summary>The purpose of this project is to see whether treatment with a thyroid hormone, called triiodothyronine or T3, following open heart surgery reduces the risk of developing atrial fibrillation.</brief_summary>
	<brief_title>Study of T3 on the Incidence of Atrial Fibrillation in Patients Undergoing Cardiac Surgery</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>1. Patients requiring CABG or valve repair/replacement surgery. 2. Patient must be able to provide informed consent. 1. Patients less than 18 or over 85 years of age. 2. Patients less than 50kg or greater than 120kg. 3. Patients currently with endocrine disorders, excluding diabetes. 4. Patients currently with thyroid dysfunction (e.g., hyper hyperthyroidism, goiter, Grave's disease), myxedema, or myxedema coma, even if treated. 5. Patients currently receiving thyroid replacement therapy. 6. Patients currently receiving Ketamine, levarterenol or dietary (nonfood) iodine supplementation. 7. Patients who have received any investigational drugs within the previous one month or five halflives of the drug. 8. Patients who are pregnant. Pregnancy testing will be done for women of childbearing potential. 9. Patients currently in atrial fibrillation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2008</verification_date>
</DOC>